SLC38A7: A Potential Drug Target Or Biomarker for Various Diseases

Target Name: SLC38A7

NCBI ID: G55238

SLC38A7: A Potential Drug Target Or Biomarker for Various Diseases

SLC38A7 (S38A7_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and kidney. It is a member of the SLC family of transport proteins, which are responsible for carrying small molecules across cell membranes. SLC38A7 has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic kidney disease.

The SLC38A7 protein is composed of 38 amino acid residues and has a calculated molecular weight of 41 kDa. It is expressed in a variety of tissues, including the brain, heart, liver, and kidney, and is predominantly expressed in the brain. SLC38A7 is a monomer and has one isoform.

SLC38A7 is involved in the transport of various small molecules across cell membranes, including neurotransmitters, such as dopamine, serotonin, and endotheliotoxins, which are released from various tissues and can cause harm if they reach unintentionally higher levels in the body. SLC38A7 is also involved in the transport of ions, such as calcium and magnesium, which are essential for various physiological functions.

SLC38A7 has been identified as a potential drug target or biomarker for a variety of diseases. For example, SLC38A7 has been shown to be overexpressed in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Elevated SLC38A7 expression has been associated with increased neurofibrillary tangles and neurodegeneration in these diseases.

In addition to its involvement in neurodegenerative diseases, SLC38A7 has also been shown to be involved in cancer. For example, SLC38A7 has been found to be overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. Elevated SLC38A7 expression has been associated with cancer cell proliferation and survival.

SLC38A7 has also been identified as a potential biomarker for chronic kidney disease. Chronic kidney disease is a serious condition that can be caused by a variety of factors, including diabetes, hypertension, and aging. SLC38A7 has been shown to be involved in the regulation of kidney function in these diseases. Elevated SLC38A7 expression has been associated with decreased kidney function and increased risk of developing chronic kidney disease.

In conclusion, SLC38A7 is a protein that is involved in the transport of various small molecules across cell membranes and has been identified as a potential drug target or biomarker for a variety of diseases, including cancer and chronic kidney disease. Further research is needed to fully understand the role of SLC38A7 in these diseases and to develop effective treatments.

Protein Name: Solute Carrier Family 38 Member 7

Functions: Symporter that selectively cotransports sodium ions and amino acids, such as L-glutamine and L-asparagine from the lysosome into the cytoplasm and may participates in mTORC1 activation (PubMed:28416685, PubMed:35561222). The transport activity requires an acidic lysosomal lumen (PubMed:28416685)

More Common Targets